dexrazoxane has been researched along with Cardiotoxicity in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 25 (59.52) | 24.3611 |
| 2020's | 17 (40.48) | 2.80 |
| Authors | Studies |
|---|---|
| Austin, CA; Bavlovič Piskáčková, H; Jirkovská, A; Jirkovský, E; Karabanovich, G; Korábečný, J; Kubeš, J; Kučera, T; Melnikova, I; Nováková, L; Roh, J; Šimůnek, T; Skalická, V; Škoda, J; Štěrba, M | 1 |
| Getz, KD; Leger, KJ; Narayan, HK | 1 |
| Gao, Y; Hu, X; Li, H; Li, M; Liang, B; Lu, Q; Xing, D; Ye, T; Yuan, Y; Zhang, Y; Zou, L | 1 |
| Abdelfattah, OM; Abela, GS; Addison, D; Awad, AK; Barac, A; Fradley, MG; Gerew, M; Ghaith, HS; Guha, A; Moustafa, K; Munir, M; Sayed, A; Shazly, O | 1 |
| Aghdam, M; Crooks, BN; Giacomantonio, N; Grandy, SA; Heinze-Milne, S; Johnston, WJ; Keats, MR; Kendall, SJ; Langley, JE; Mulvagh, SL | 1 |
| Andelfinger, G; Caru, M; Curnier, D; Krajinovic, M; Lapointe, MO; Laverdière, C; Périé, D; Raboisson, MJ; Sinnett, D | 1 |
| Armenian, S; de Baat, EC; Feijen, EA; Grotenhuis, H; Hudson, MM; Kremer, LC; Mavinkurve-Groothuis, AM; Mulder, RL; van Dalen, EC | 1 |
| Amin Hashemipour, SM; Hosseinpour, H; Keshavarzian, E; Khamas, SS; Kogani, M; Moazen, M; Mortazavizadeh, SM; Motevalipoor, AF; Sadighpour, T; Soltani, M; Valizadeh, R | 1 |
| Ait-Oudhia, S; Mody, H; Vaidya, TR | 1 |
| Al-Hussaniy, HA; Al-Samydai, AM; Al-Tameemi, ZS; Al-Zobaidy, MAJ; Alburghaif, AH; Alkhafaje, Z; Alkuraishy, HM; Azam, F; Mostafa-Hedeab, G; Naji, MA | 1 |
| Armenian, SH; de Baat, EC; Feijen, EAM; Kremer, LCM; Mavinkurve-Groothuis, AMC; Mulder, RL; van Dalen, EC | 1 |
| Bosman, M; De Meyer, GRY; Favere, K; Franssen, C; Guns, PJ; Krüger, DN; Van Craenenbroeck, EM | 1 |
| Corrêa, FM; Fernandes, RRA; Freitas, PG; Guerra, RL; Vianna, CMM | 1 |
| Cai, L; Ji, H; Keller, BB; Leng, J; Yu, H; Zhen, J | 1 |
| Hasinoff, BB; Patel, D; Wu, X | 1 |
| Dou, L; Huang, X; Jin, Z; Li, J; Man, Y; Qiu, Q; Ruan, Y; Shen, T; Sun, S; Tang, W; Wang, Q; Yan, M; Yu, X; Zhang, X | 1 |
| Adamcová, M; Bavlovič Piskáčková, H; Jirkovská, A; Jirkovský, E; Karabanovich, G; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Roh, J; Šimůnek, T; Skalická, V; Štěrba, M; Štěrbová-Kovaříková, P | 1 |
| Bavlovič Piskáčková, H; Chládek, J; Jansová, H; Jirkovská, A; Karabanovich, G; Kollárová-Brázdová, P; Kubeš, J; Lenčová-Popelová, O; Melnikova, I; Roh, J; Šimůnek, T; Štěrba, M; Štěrbová-Kovaříková, P; Váňová, N | 1 |
| Benjamin, RS; Minotti, G | 1 |
| Holt, GE; Lipshultz, ER; Lipshultz, SE; Ramasamy, R; Yechieli, R | 1 |
| Amdani, S; Bansal, N; Lipshultz, ER; Lipshultz, SE | 1 |
| Bures, J; Jansova, H; Jirkovska, A; Karabanovich, G; Kovarikova, P; Roh, J; Sestak, V; Simunek, T; Sterba, M | 1 |
| Chan, M; Chiu, B; Harris, J; Liesse, K; Schmidt, ML | 1 |
| Jones, RL; Mora, J; Morland, B; Reichardt, P; Tabone, MD | 1 |
| Ahn, HS; Baek, HJ; Cho, B; Choi, HS; Chueh, HW; Chung, NG; Hah, JO; Hahn, S; Im, HJ; Kang, HJ; Kawano, Y; Kim, H; Kim, HK; Kim, HM; Kim, HS; Kim, JY; Koh, KN; Kook, H; Lee, JA; Lee, JM; Lee, JW; Lee, MJ; Lee, YH; Park, JW; Park, KD; Park, M; Park, SK; Seo, JJ; Shin, HY; Yoon, HS | 1 |
| Atienza, V; Avetisyan, R; Chen, M; Gao, C; Hoang, J; Jia, Y; Lue, Y; Rao, M; Ren, S; Song, Y; Swerdloff, R; Wang, C; Wang, Y; Yu, J; Zhang, Y | 1 |
| Amdani, SM; Bansal, N; Hutchins, KK; Lipshultz, SE | 1 |
| Desai, VG; Fuscoe, JC; Han, T; Herman, EH; Lee, T; Lewis, SM; Moland, CL; Vijay, V | 1 |
| Bentley, RA; Colley, HE; Copple, IM; Cross, MJ; Lu, ZQ; Murdoch, C; Sharma, P; Tomlinson, L; Webb, SD | 1 |
| He, LH; Hu, KY; Jia, ZR; Li, SR; Li, XJ; Mao, J; Tian, W; Wang, DW; Yang, Y; Zhang, W | 1 |
| Colan, SD; Franco, VI; Lipshultz, SE; Miller, TL; Sallan, SE | 1 |
| Liu, J; Meng, T; Zhang, J; Zhang, S; Zhang, X | 1 |
| Geng, C; Li, X; Qi, X; Sun, F | 1 |
| Andelfinger, G; Ansari, M; Bertout, L; Drouin, S; Elbared, J; Krajinovic, M; Kutok, JL; Laverdière, C; Lipshultz, SE; Neuberg, DS; Raboisson, MJ; Rezgui, A; Sallan, SE; Silverman, LB; Sinnett, D | 1 |
| Franco, VI; Lipshultz, SE | 1 |
| Armenian, SH; Asselin, BL; Borowitz, MJ; Camitta, BM; Chen, L; Devidas, M; Franco, VI; Hutchison, RE; Lipshultz, SE; Pullen, J; Ravindranath, Y | 1 |
| Adamcová, M; Chládek, J; Geršl, V; Hroch, M; Jansová, H; Jirkovská-Vávrová, A; Jirkovský, E; Lenčová-Popelová, O; Mazurová, Y; Pokorná, Z; Šimůnek, T; Štěrba, M; Vostatková-Tichotová, L | 1 |
| Al-Harbi, NO | 1 |
| Busemann, C; Ehninger, G; Gerdes, S; Hentschel, L; Kopp, HG; Lenz, F; Pink, D; Reichardt, P; Richter, S; Schuler, MK; West, A | 1 |
| Franco, VI; Hutchins, KK; Lipshultz, SE; Siddeek, H | 1 |
| Chen, JJ; Middlekauff, HR; Nguyen, KL; Wu, PT | 1 |
| Cheng, G; GenJin, Y; Jie, L; Jin, L; JinLu, H; LiLi, W; QuanJun, Y; Run, G; Yan, H; YongLong, H | 1 |
14 review(s) available for dexrazoxane and Cardiotoxicity
| Article | Year |
|---|---|
Nicotinic Acid Riboside Regulates Nrf-2/P62-Related Oxidative Stress and Autophagy to Attenuate Doxorubicin-Induced Cardiomyocyte Injury.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Doxorubicin; Humans; Niacinamide; Oxidative Stress; Pyridinium Compounds | 2022 |
Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysis.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bayes Theorem; Cardiotoxicity; Dexrazoxane; Female; Heart Failure; Humans; Hypotension; Male; Mineralocorticoid Receptor Antagonists; Network Meta-Analysis; Stroke Volume; Ventricular Function, Left | 2022 |
The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review.
Topics: Anthracyclines; Cancer Survivors; Cardiotoxicity; Dexrazoxane; Heart Diseases; Humans; Neoplasms; Survivors | 2022 |
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
Topics: Adult; Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Heart Failure; Humans; Leukemia, Myeloid, Acute; Polyketides; Systematic Reviews as Topic | 2022 |
Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiotoxicity; Dexrazoxane; Humans; Idarubicin; Neoplasms | 2023 |
Chemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs.
Topics: Anthracyclines; Antineoplastic Agents; Cardiotoxicity; Dexrazoxane; Digoxin; Humans; Polyketides; Resveratrol | 2023 |
Chemotherapy-induced cardiotoxicity in children.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Dose-Response Relationship, Drug; Female; Humans; Male; Neoplasms; Primary Prevention; Risk Factors | 2017 |
Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.
Topics: Adolescent; Anthracyclines; Cardiotoxicity; Child; Child, Preschool; Dexrazoxane; Disease-Free Survival; Female; Humans; Infant; Male; Neoplasms; Survival Rate | 2018 |
Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
Topics: Adolescent; Anthracyclines; Antibiotics, Antineoplastic; Cardiotoxicity; Child; Dexrazoxane; Humans; Neoplasms, Second Primary | 2018 |
Cardiovascular disease in survivors of childhood cancer.
Topics: Adult Survivors of Child Adverse Events; Anthracyclines; Antineoplastic Agents; Cancer Survivors; Cardiotonic Agents; Cardiotoxicity; Cardiovascular Diseases; Dexrazoxane; Humans | 2018 |
Cardiovascular disease in adult survivors of childhood cancer.
Topics: Adult; Antineoplastic Agents; Cardiotonic Agents; Cardiotoxicity; Cardiovascular Diseases; Child; Dexrazoxane; Doxorubicin; Humans; Neoplasms; Survivors | 2015 |
Cardiac complications in childhood cancer survivors treated with anthracyclines.
Topics: Anthracyclines; Antineoplastic Agents; Cardiotoxicity; Dexrazoxane; Heart Failure; Humans; Neoplasms; Pediatrics; Risk Factors; Survivors | 2015 |
Prevention of cardiotoxicity among survivors of childhood cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cancer Survivors; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Humans; Models, Cardiovascular | 2017 |
Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
Topics: Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Exercise; Exercise Therapy; Heart Diseases; Humans; Neoplasms; Survivors | 2017 |
3 trial(s) available for dexrazoxane and Cardiotoxicity
| Article | Year |
|---|---|
Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotonic Agents; Cardiotoxicity; Cyclophosphamide; Dexrazoxane; Diabetes Mellitus, Type 2; Drug Monitoring; Epirubicin; Female; Heart Function Tests; Humans; Middle Aged; Treatment Outcome | 2015 |
Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Child, Preschool; Dexrazoxane; Doxorubicin; Female; Genetic Predisposition to Disease; Heart Diseases; Heterozygote; Homozygote; Humans; Infant; Male; Multidrug Resistance-Associated Proteins; Myocardial Contraction; Nitric Oxide Synthase Type III; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protective Factors; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Young Adult | 2016 |
Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Grou
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Doxorubicin; Female; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome; Troponin T | 2016 |
25 other study(ies) available for dexrazoxane and Cardiotoxicity
| Article | Year |
|---|---|
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Diketopiperazines; DNA Topoisomerases, Type II; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Myocytes, Cardiac; Piperazines; Protein Binding; Rats, Wistar; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2021 |
Minimizing cardiac toxicity in children with acute myeloid leukemia.
Topics: Adolescent; Anthracyclines; Antineoplastic Agents; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Female; Heart; Humans; Leukemia, Myeloid, Acute | 2021 |
Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments.
Topics: Cardiotoxicity; Dexrazoxane; Doxorubicin; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stroke Volume; Survivors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2023 |
In vitro to clinical translational pharmacokinetic/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization.
Topics: Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Doxorubicin; Humans; Myocytes, Cardiac | 2023 |
Comment on: Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Child; Dexrazoxane; Humans; Neoplasms; Polyketides; Razoxane | 2023 |
Dexrazoxane does not mitigate early vascular toxicity induced by doxorubicin in mice.
Topics: Acetylcholine; Animals; Antibiotics, Antineoplastic; Cardiotoxicity; Dexrazoxane; Doxorubicin; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Reactive Oxygen Species | 2023 |
[Economic assessment of dexrazoxane in prophylaxis of cardiotoxicity in children undergoing chemotherapy with anthracyclines].
Topics: Age Factors; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Child; Child, Preschool; Cost-Benefit Analysis; Dexrazoxane; Female; Heart; Heart Failure; Humans; Male; Neoplasms | 2019 |
Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Topics: Animals; Animals, Newborn; Cardiotoxicity; Dexrazoxane; Disease Models, Animal; DNA Topoisomerases, Type II; Doxorubicin; Iron Chelating Agents; Metallothionein; Mice; Mice, Transgenic; Myocytes, Cardiac; Reactive Oxygen Species; Tissue Engineering | 2019 |
The Role of Topoisomerase IIβ in the Mechanisms of Action of the Doxorubicin Cardioprotective Agent Dexrazoxane.
Topics: Animals; Animals, Newborn; Cardiotoxicity; Cells, Cultured; Dexrazoxane; DNA Topoisomerases, Type II; Doxorubicin; Female; Heart Diseases; Male; Myocytes, Cardiac; Primary Cell Culture; Rats, Sprague-Dawley; Signal Transduction; Time Factors; Topoisomerase II Inhibitors | 2020 |
Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p.
Topics: Animals; Apoptosis; Cardiotoxicity; Cell Survival; Dexrazoxane; Disease Models, Animal; Doxorubicin; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Myocytes, Cardiac; Protective Agents; PTEN Phosphohydrolase; Up-Regulation | 2020 |
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Topics: Animals; Anthracyclines; Cardiomyopathies; Cardiotoxicity; Cell Line, Tumor; Dexrazoxane; DNA Topoisomerases, Type II; Heart; HL-60 Cells; Humans; Male; Models, Animal; Myocardium; Myocytes, Cardiac; Protective Agents; Rabbits; Rats; Rats, Wistar; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2020 |
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Topics: Animals; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Male; Myocytes, Cardiac; Piperazine; Prodrugs; Rabbits; Razoxane; Topoisomerase II Inhibitors; Water | 2021 |
Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection.
Topics: Cardiotoxicity; Dexrazoxane; Doxorubicin; Humans; Razoxane; Sarcoma | 2021 |
Fertility, Cardiac, and Orthopedic Challenges in Survivors of Adult and Childhood Sarcoma.
Topics: Adolescent; Adult; Bone Neoplasms; Cancer Survivors; Cardiotoxicity; Child; Cisplatin; Dexrazoxane; Doxorubicin; Female; Humans; Infertility; Male; Methotrexate; Osteosarcoma | 2017 |
Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite.
Topics: Animals; Animals, Newborn; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Cell Proliferation; Cells, Cultured; Daunorubicin; Dexrazoxane; Diketopiperazines; DNA Topoisomerases, Type II; Iron; Iron Chelating Agents; Myocytes, Cardiac; Rats; Rats, Wistar; Structure-Activity Relationship | 2017 |
Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.
Topics: Adolescent; Adult; Anthracyclines; Cardiotonic Agents; Cardiotoxicity; Child; Child, Preschool; Dexrazoxane; Factor Analysis, Statistical; Female; Humans; Incidence; Infant; Infant, Newborn; Male; Multivariate Analysis; Neoplasms; Neoplasms, Second Primary; Republic of Korea; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2019 |
Humanin analog enhances the protective effect of dexrazoxane against doxorubicin-induced cardiotoxicity.
Topics: Animals; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Doxorubicin; Drug Synergism; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac | 2018 |
Candidate early predictive plasma protein markers of doxorubicin-induced chronic cardiotoxicity in B6C3F
Topics: Administration, Intravenous; Animals; Antibiotics, Antineoplastic; Biomarkers; Cardiotoxicity; Dexrazoxane; Doxorubicin; Heart; Male; Mice; Myocardium; Protective Agents; Proteome; Proteomics; Receptor, Notch1; Risk Assessment; von Willebrand Factor | 2019 |
Attenuation of doxorubicin-induced cardiotoxicity in a human in vitro cardiac model by the induction of the NRF-2 pathway.
Topics: Antibiotics, Antineoplastic; Cardiotoxicity; Cell Survival; Dexrazoxane; Doxorubicin; Drug Synergism; Heart; Humans; In Vitro Techniques; Isothiocyanates; NF-E2-Related Factor 2; Oleanolic Acid; Reactive Oxygen Species; Spheroids, Cellular; Sulfoxides | 2019 |
[Prevention against and treatment of doxorubicin-induced acute cardiotoxicity by dexrazoxane and schisandrin B].
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Cardiomyopathies; Cardiotoxicity; Cyclooctanes; Dexrazoxane; Doxorubicin; Heart; Lignans; Myocardium; Polycyclic Compounds; Rats; Rats, Sprague-Dawley | 2014 |
Cardiac protective effects of dexrazoxane on animal cardiotoxicity model induced by anthracycline combined with trastuzumab is associated with upregulation of calpain-2.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Calpain; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Doxorubicin; Heart Ventricles; Malondialdehyde; Models, Animal; Myocytes, Cardiac; Random Allocation; Rats, Inbred F344; RNA, Messenger; Stroke Volume; Trastuzumab; Troponin I; Ultrasonography; Up-Regulation | 2015 |
Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.
Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Daunorubicin; Dexrazoxane; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Administration Schedule; Infusions, Intravenous; Male; Myocardium; Myocytes, Cardiac; Nitrates; Rabbits; Sodium Nitrite | 2016 |
Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Gene Expression; Male; Oligopeptides; Oxidative Stress; Rats, Wistar; Ventricular Myosins | 2016 |
Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Dexrazoxane; Disease-Free Survival; Female; Free Radical Scavengers; Heart; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Young Adult | 2016 |
Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Dexrazoxane; Doxorubicin; Glucose; Heart Diseases; Lipid Metabolism; Male; Metabolome; Metabolomics; Mice; Nuclear Magnetic Resonance, Biomolecular; Oxidation-Reduction | 2017 |